

S710
24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
Introduction
Emotion regulation (ER) efficiency dwells among
the most pressing issues of contemporary psychology and psychi-
atry. Further development of the methods of reliable assessments
for ER makes it the task of current importance.
Objective
To modify Rosenzweig Picture-Frustration Test for the
study of ER in health and in disease.
Methods
In the initial stage of testing participants had to look
through a succession of Rosenzweig’s pictures, and select poten-
tially traumatizing situations.
In the second stage they answered the following questions:
– what would you say in this particular situation?
– what would you have in mind, saying this?
– could you think of an answer that would taper down the
traumatizing character of the situation in your own perception?
(Zinchenko, Pervichko, 2014).
A total of 85 patients with stress-induced hypertension (mean age
was 45.9
±
2.8) and 82 healthy subjects (mean age was 44.9
±
3.1)
took part in the study.
Results
We came to distinguish among four classes of ER strate-
gies: internal, cognitively non-mediated; internal, cognitively
transforming; external, cognitively non-mediated; and external,
cognitively transforming (Pervichko, 2015). Hypertensive patients
significantly more frequently than healthy subjects reveal wider
set of emotionally grave events (19.8% vs 11.2%,
P
< 0.001), they
are more prone to rumination, disasterization (19.0% vs 11.1%,
P
< 0.001) and suppression in display of their emotions (31.9% vs
20.2%,
P
< 0.001). The patients will seldom employ the strategy
of interactive subject–subject transformations; their capability to
actualize new meanings in traumatic situations is diminished.
Conclusions
Application of the described modification of Rosen-
zweig Picture-Frustration Test allows to distinguish and classify
various ER strategies, and to demonstrate peculiarities in ER related
behaviour of hypertensive patients as opposed to healthy subjects.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.2115EV1131
New methodologies for faster study of
new psychoactive substances: A
proposal
P. Quintana Mathé
1 , 2 ,∗
, M. Grifell
1 , 2 , 31
Hospital del Mar Medical Research Institute, Grup de Recerca en
Addiccions, Barcelona, Spain
2
Associació Benestar i Desenvolupament, Energy Control, Barcelona,
Spain
3
Parc de Salut Mar, Institut de Neuropsiquiatria i Addiccions,
Barcelona, Spain
∗
Corresponding author.
Introduction
New psychoactive substances (NPS) are substances
that have recently become available, and are not worldwide reg-
ulated. They often intend to mimic the effect of controlled drugs,
becoming a public health concern. In 2014, 101 substances were
reported for the first time in the EU, whichmay require to be studied
and risk-assessed by the scientific community. The EMCDDA rec-
ognizes it as an emerging topic where research is most needed, as
the scientific community is struggling to keep pace with the speed
at which new substances appear. On the one hand, case reports
and internet-based surveys are quickly published but do not pro-
vide enough evidence to guide clinical decisions. On the other hand,
classical high-reliability methodologies such as Cohort and Clinical
studies take too long and their cost is too high to be of much use
for the study of NPS. We propose an intermediate methodology to
tackle this unmet need.
Rationale
González and colleagues described a set of highly edu-
cated, experimental users of NPS with extensive knowledge and
consumption of substances. These users usually look for drug
checking of the substances they intend to consume. We suggest
we could benefit from the collaboration of such users, and the pos-
sibility of obtaining analytical confirmation, to retrieve information
about NPS in a quick and reliable fashion.
Outline of methodology
Recluting of subjects that submit NPS to a
drug checking facility. Analysis of the samples for analytical confir-
mation. Check inclusion criteria and propose inclusion in the study.
Give structured forms for reporting effects and adverse events.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.2116Schizophrenia
EV1132
Self-continuity across time in
schizophrenia: An exploration of
phenomenological and narrative
continuity in the past and future
M. Allé
1 ,∗
, A. D’Argembeau
2, P. Schneider
1, J. Potheegadoo
1,
R. Coutelle
3, J.M. Danion
1, F. Berna
11
Inserm, U1114, Strasbourg, France
2
University of Liège, Psychology Department, Liège, Belgium
3
Psychotherapy center of Nancy, Autism Ressources Center, Laxou,
France
∗
Corresponding author.
Disorders of the self, such as the “loss of continuity” of the self
in time, are a core symptom of schizophrenia, but one, which is
still poorly understood. In the present study, we investigated two
complementary aspects of self-continuity, namely phenomenolog-
ical and narrative continuity, in 27 patients with schizophrenia,
and compared themwith 27 control participants. Participants were
asked to identify 7 important past events and to narrate a story
taken from their life that included these events. They were then
asked to imagine 3 important events thatmight happen in their per-
sonal future and to build a narrative of their future life. Thememory
vividness of these important life-events and the proportion of
self-event connections in the narratives were used as a measure
of phenomenological and narrative continuity, respectively. Our
results showed that the difficulty for patients to construct vivid
representations of personally significant events was observed in
both temporal directions, past and future. Patients’ ability to estab-
lish explicit connections between personal events and attributes
of self in life narratives was also impaired, but only in the case of
past narratives. Our results yield a fresh understanding of the cog-
nitive mechanisms of self-disorders in schizophrenia. The clinical
and therapeutic implications of these findings are discussed.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.2117EV1133
Population pharmacokinetic
modeling and simulations of
dopamine Dd2 receptor occupancy of
long-acting intramuscular
risperidone-ISM
J. Llaudó
1 , L. Anta
1 , I. Ayani
1 ,∗
, J. Martínez-González
1 ,I. Gutierro
2 , R. Faelens
3 , J. Winkler
3 , E. Snoeck
31
Laboratorios Farmacéuticos Rovi-S.A., Medical Department, Madrid,
Spain